News - Page 741

Increased Venture Capital Investment Bolsters Women’s Health Startups This article discusses the increase in venture capital investment in startups addressing women’s health. According to a report from Silicon Valley Bank (SVB), investment

TLDR: – Israeli venture studio AION Labs has announced a strategic partnership with early-stage VC firm Amiti Ventures. – The partnership aims to advance healthcare towards more patient-centric precision medicine and bring

Increased Venture Capital Investment Bolsters Women’s Health Startups Summary: Investment in women’s health startups increased 314% since 2018, compared to an overall increase of 28% in health sector investment. Women’s health companies

TL;DR: Venrock, one of Silicon Valley’s oldest and most respected venture capital firms, has raised $650m for its tenth fund, the largest it has raised in over a decade. The firm plans

TLDR: Veteran-centric venture capital fund, Zigr Inc., has launched GOVFUND.US, a VC fund for accredited investors in the aerospace, defense, government, and technology sectors. Fund Manager Jesse Mauck, Director of Zigr Inc.,

TLDR: – Cure Ventures has hired former executives from Sage Therapeutics to invest in neuroscience startups. – This move highlights the growing interest in neuroscience startups within the venture capital realm. In

In 2024, venture capitalists are cautiously optimistic about the state of the venture market. After a turbulent few years, funding is expected to stabilize, exit markets are anticipated to recover, and the

TLDR: – Taiho Ventures, a strategic corporate venture capital arm of Taiho Pharmaceutical, has increased its investment pool from $300 million to $400 million. – The firm seeks to invest in promising

TLDR: Biotech VC Cure Ventures has hired former executives from Sage Therapeutics, Jeff Jonas and Al Robichaud, as partners. Cure Ventures plans to use their expertise to invest in neuroscience startups. Jonas

TLDR: According to a new report from J.P. Morgan, antibody-drug conjugates (ADCs) were the hottest ticket in the biopharma industry in 2023, driving a spike in licensing deal proceeds. Despite a decrease